Hemostatic changes in patients with end stage renal disease undergoing hemodialysis

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 135-139

  Rios, Danyelle Romana Alves ^a   Carvalho, Maria das Graças ^a   Lwaleed, Bashir A ^a   Simões e Silva, Ana Cristina ^a   Borges, Karina Braga Gomes ^a   Dusse, Luci Maria SantAna ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Coagulation; End stage renal disease; Fibrinolysis; Hemodialysis; Platelets

Indexed keywords

HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; HYPERCOAGULABILITY; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOSIS; UREMIA; VASCULAR ACCESS THROMBOSIS;

BLOOD CIRCULATION; BLOOD PLATELETS; FIBRINOLYSIS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

FISTULA;

EID: 72449197127     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.11.022     Document Type: Review

References (78)

1. Jubelirer S.J. Hemostatic abnormalities in renal disease. Am J Kidney Dis 5 (1985) 219-225
2. Erdem Y., Haznedaroglu I.C., Celik I., et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 11 (1996) 1299-1305
3. Yu A., Egberg N., and Jacobson S.H. Haemostatic complications in haemodialysis patients: effect of type of vascular access and dialysis filter. Scand J Clin Lab Invest 63 (2003) 127-134
4. Bronisz M., Rosé D., Bronisz A., Manitius J., and Nartowicz E. The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure. Ren Fail 26 (2004) 223-229
5. Knoll G.A., Wells P.S., Young D., et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 16 (2005) 1108-1114
6. Windus D.W., Santoro S., and Royal H.D. The effects of hemodialysis on platelet deposition in prosthetic graft fistulas. Am J Kidney Dis 26 (1995) 614-621
7. Porile J.L., and Richter M. Preservation of vascular access. J Am Soc Nephrol 4 (1993) 997-1003
8. Goldwasser P., Avram M.M., Collier J., Michel M.A., Gusik S.A., and Mittman N. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 24 (1994) 785-794
9. Goldwasser P., Michel M.A., Collier J., et al. Prealbumin and lipoprotein (a) in hemodialysis: relationship with patient and vascular access survival. Am J Kidney Dis 22 (1993) 215-225
10. Castaldi P.A., Rozenberg M.C., and Stewart J.H. The bleeding disorder of uremia: a qualitative platelet defect. Lancet 2 (1966) 66-69
11. Larsson S.O. On coagulation and fibrinolysis in renal failure. Scand J Haematolol Suppl 15 (1971) 1-59
12. Salzman E.W., and Neri L.L. Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh 15 (1966) 84-92
13. Horowitz H.I., Stein I.M., Cohen B.D., and White J.G. Further studies on the platelet inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 49 (1970) 336-345
14. Remuzzi G., Benigni A., Dodesini P., et al. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest 71 (1983) 762-768
15. Mathias F.R., and Palinski W. Prostaglandin-endoperoxides and cyclic 3′5′-AMP in platelets of patients with uremia. Thromb Haemost 38 (1977) 34
16. Lewis J.H., Zucker M.B., and Fergunson J.H. Bleeding tendency in uremia. Blood 11 (1956) 1073-1076
17. Sloand E.M., Sloand J.A., Prodouz K., et al. Reduction of platelet glycoprotein Ib in uremia. Br J Haematolol 77 (1991) 375-381
18. Bazilinski N., Shaykh M., Dunea G., et al. Inhibition of platelet function by uremic middle molecules. Nephron 40 (1985) 423-428
19. Davis J.W., Mcfield J.R., Phillips P.E., and Graham B.A. Guanidinosuccinic acid on human platelet: effects of exogenous urea, creatinine, and aggregation in vitro. Blood 39 (1972) 388-397
20. Eknoyan G., Wacksman S.J., Glueck H.I., and Will J.J. Platelet function in renal failure. N Engl J Med 280 (1969) 677-681
21. Rabiner S.F., and Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 49 (1970) 346-351
22. Zwaginga J.J., Ijsseldijk M.J., de Groot P.G., Vos J., de Bos Kuil R.L., and Sixma J.J. Defects in platelet adhesion and aggregate formation in uremic bleeding disorders an be attributed to factors in plasma. Arterioscler Thromb 11 (1991) 733-744
23. Sloand J.A., and Sloand E.M. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 8 (1997) 799-803
24. Sreedhara R., Itagaki I., and Hakim R.M. Uremic platelets have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 27 (1996) 355-364
25. Kozek-Langenecker S.A., Masaki T., Mohammad H., Green W., Mohammad S.F., and Cheung A.K. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 56 (1999) 299-305
26. Liani M., Salvati F., Golato M., and Tresca E. Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron 72 (1996) 716
27. Moal V., Brunet P., Dou L., Morange S., Sampol J., and Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 18 (2003) 1834-1841
28. Salvati F., and Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 24 (2001) 131-135
29. Malyszko J.S., Malyszko J.S., Pawlak D., Pawlak K., Buczko W., and Mysliwiec M. Hemostasis, platelet function and serotonin in acute and chornic renal failure. Thromb Res 83 (1996) 351-361
30. Liani M., Salvati F., Tresca E., et al. Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand factor and for fibrinogen (glycoproteins GPIIb/IIIa) in haemodialysis patients. Int J Artif Organs 19 (1996) 451-454
31. Cases A., Reverter J.C., Escolar G., et al. Platelet activation on hemodialysis: influence of dialysis membranes. Kidney Int Suppl 43 (1993) S217-S220
32. Hakim R.M., and Schafer A.I. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 78 (1985) 575-580
33. Turitto V.T., and Hall C.L. Mechanical factors affecting hemostasis and thrombosis. Thromb Res 92 (1998) S25-S31
34. Viener A., Aviram M., Better O.S., and Brook J.G. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 43 (1986) 139-143
35. Salzman E.W., Lindon J., Mcmanama G., and Ware J.A. Role of fibrinogen in activation of platelets by artificial surfaces. Ann N Y Acad Sci 516 (1987) 184-195
36. Savage B., and Ruggeri Z.M. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb/IIIa on nonactivated platelets. J Biol Chem 266 (1991) 11227-11233
37. Colman R.W., Scott C.F., Schmaier A.H., Wachtfogel Y.T., Pixley R.A., and Edmunds L.H. Initiation of blood coagulation at artificial surfaces. Ann N Y Acad Sci 516 (1987) 253-267
38. Smits J.H.M., Linden J., Blankestijn P.J., and Rabelink T.J. Coagulation and hemodialysis access thrombosis. Nephrol Dial Transplant 15 (2000) 1755-1760
39. Chuang Y.C., Chen J.B., Yang L.C., and Kuo C.Y. Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transpl 18 (2003) 947-954
40. Bartels P.C.M., Schoorl M., Schoorl M., and Nubé M.J. Deviations in coagulation activation due to treatment with different haemodialysis membranes. Scand J Clin Lab Invest 63 (2003) 417-424
41. Sabovic M., Salobir B., Zupan I.P., Bratina P., Bojec V., and Ponikvar J.B. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 34 (2005) 274-278
42. Fischer K.G. Essentials of anticoagulation in hemodialysis. Hemodial Int 11 (2007) 178-189
43. Malyszko J., Malyszko J.S., and Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Intern 21 (2001) 158-165
44. Gordge M.P., and Neild G.H. Platelet function in uremia. Platelets 2 (1991) 115-123
45. Ishii H., Uchiyama H., and Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65 (1991) 618-623
46. Gris J.C., Branger B., Vécina F., Al Sabadami B., Fourcade J., and Schved J.F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialysed uremic patients. Kidney Int 46 (1994) 807-813
47. Hergesell O., Andrassy K., Geberth S., Nawroth P., and Gabath S. Plasma thrombomodulin levels are dependent on renal function. Thromb Res 72 (1993) 455-458
48. Takagi M., Wada H., Mukai K., et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis 5 (1994) 713-717
49. Kario K., Matsuo T., Yamada T., and Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 71 (1994) 275-279
50. Koyama T., Nishida K., Ohdama S., et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 87 (1994) 343-347
51. Hong S.Y., and Yang D.H. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron 68 (1994) 329-333
52. Nakamura Y., Tomura S., Tachibana K., Chida Y., and Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 38 (1992) 90-96
53. Mezzano D., Tagle R., and Pais E. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 88 (1997) 465-472
54. Mezzano D., Tagle R., Panes O., et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 76 (1996) 312-321
55. Mezzano D., Pais E., Aranda E., et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60 (2001) 1844-1850
56. Rabelink T.J., Zwaginga J.J., Koomans H.A., and Slxma J.J. Thrombosis and hemostasis in renal failure. Kidney Int 46 (1994) 287-296
57. Vaziri N.D., Gonzales E.C., Wang J., and Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 23 (1994) 828-835
58. Sagripanti A., Cupisti A., Baicchi U., Ferdeghini M., Morelli E., and Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 63 (1993) 273-278
59. Lai K., Yin J.A., Yuen P.M.P., and Li P.K.T. Effect of hemodialysis on protein C, protein S and a antithrombin III levels. Am J Kidney Dis 17 (1991) 38-42
60. De Marchi S., Falleti E., Giacomello R., et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 7 (1996) 1169-1177
61. Ambühl P.M., Wüthrich R.P., Korte W., Schmid L., and Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 12 (1997) 2355-2364
62. Song S., Yang W.S., Kim S.B., Lee J., Kwon T., and Park J.S. Association of plasma fibrinogen concentration with vascular access failure in haemodialysis patients. Nephrol Dial Transplant 14 (1999) 137-141
63. Kushiya F., Wada H., Sakakura M., et al. Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis. Clin Appl Tromb Hemost 9 (2003) 53-60
64. Nampoory M.R., Das K.C., Johny K.V., et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 42 (2003) 797-805
65. Inoue A., Wada H., and Takagi M. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Tromb Hemost 6 (2000) 100-103
66. Yorioka N., Taniguchi Y., Yamashita K., et al. Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Int J Artif Organs 21 (1998) 699-701
67. Kario K., Matsuo T., Matsuo M., et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 73 (1995) 763-767
68. Cella G., Vertolli U., Naso A., et al. Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb Res 81 (1996) 671-677
69. Salobir B., Sabovic M., Zupan I.P., and Ponikvar J.B. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients. Ther Apher Dial. 12 2 (2008) 133-136
70. Costa E., Rocha S., Rocha-Pereira P., et al. Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. J Vasc Access 9 (2008) 248-253
71. O'shea S.I., Lawson J.H., Reddan D., Murphy M., and Ortel T.L. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38 (2003) 541-548
72. Fodinger M., Mannhalter C., Pabinger I., et al. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transpl 11 (1996) 668-672
73. Atac B., Yakupoglu U., Ozbek N., Ozdemir F.N., and Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transpl Proc 34 (2002) 2030-2032
74. Akman B., Afsar B., Ataç F.B., et al. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transpl Proc 38 (2006) 413-415
75. Shemin D., Lapane K.L., Bausserman L., et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 10 (1999) 1095-1099
76. Mallamaci F., Bonanno G., Seminara G., et al. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 45 (2005) 702-707
77. Manns B.J., Burgess E.D., Parsons H.G., Schaefer J.P., Hyndman M.E., and Scott-Douglas N.W. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 55 (1999) 315-320
78. Fukasawa M., Matsushita K., Kamiyama M., et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 41 (2003) 637-642